CN112062697A - M-benzene polyphenol derivative and preparation method thereof - Google Patents

M-benzene polyphenol derivative and preparation method thereof Download PDF

Info

Publication number
CN112062697A
CN112062697A CN201910430644.7A CN201910430644A CN112062697A CN 112062697 A CN112062697 A CN 112062697A CN 201910430644 A CN201910430644 A CN 201910430644A CN 112062697 A CN112062697 A CN 112062697A
Authority
CN
China
Prior art keywords
compound
formula
reagent
sodium
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910430644.7A
Other languages
Chinese (zh)
Other versions
CN112062697B (en
Inventor
孙长亮
朱富强
公绪栋
蒋翔锐
田广辉
沈敬山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Vigonvita Life Sciences Co ltd
Shanghai Institute of Materia Medica of CAS
Topharman Shanghai Co Ltd
Original Assignee
Suzhou Vigonvita Life Sciences Co ltd
Shanghai Institute of Materia Medica of CAS
Topharman Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Vigonvita Life Sciences Co ltd, Shanghai Institute of Materia Medica of CAS, Topharman Shanghai Co Ltd filed Critical Suzhou Vigonvita Life Sciences Co ltd
Priority to CN201910430644.7A priority Critical patent/CN112062697B/en
Publication of CN112062697A publication Critical patent/CN112062697A/en
Application granted granted Critical
Publication of CN112062697B publication Critical patent/CN112062697B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/293—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The invention relates to an m-benzene polyphenol derivative and a preparation method thereof. The synthesis method of the invention can be very simply and conveniently applied to the synthesis preparation of other derivatives and analogues of cannabidiol, greatly improves the selectivity, avoids the generation of regioisomers and disubstituted by-products to the maximum extent, and obviously improves the yield. The method has the advantages of low material cost, less pollutants, simple and convenient operation, easy expanded application of a synthetic route and the like. In addition, the method specially designed by the invention can reduce byproducts, so the method can be carried out by using a one-pot method, thereby greatly reducing the product and energy consumption during the purification by a step method and greatly reducing pollutants.

Description

M-benzene polyphenol derivative and preparation method thereof
Technical Field
The invention belongs to the field of chemical synthesis, and particularly relates to an m-benzene polyphenol derivative and a preparation method thereof.
Background
The m-phenylpolyol compounds or their derivatives are a large family of compounds, such as resorcinol, including many natural product molecules, physiologically active molecules, pharmaceutically active ingredients and their prodrug compounds. One important member is the drug Cannabidiol (CBD). Cannabidiol (CBD) is a non-addictive component of cannabis, has no hallucinogenic effect, and has wide application in the medical field. The application includes protecting nervous system, such as antispasmodic, anxiolytic, antiepileptic, analgesic, anti-inflammatory, and antirheumatic effects. Therefore, it can be used for treating various difficult and complicated diseases. In addition, a series of resorcinol compounds or derivatives thereof are synthesized through chemical structure simulation modification of Cannabidiol (CBD). The compounds have different pharmacological activities and pharmacokinetic properties, can be used for different disease treatments and medicinal purposes, and therefore have very wide application prospects and medical values.
This series of compounds can be prepared by chemical synthesis. The chemical synthesis method comprises the condensation reaction of olive alcohol (OLV) and trans-menthyl-2, 8-diene-1-alcohol ((+) - (1s,4R) -p-mentha-2,8-dien-1-ol), the condensation reaction of olive alcohol benzoate and trans-menthyl-2, 8-diene-1-alcohol, the condensation reaction of dihalide olive alcohol and trans-menthyl-2, 8-diene-1-alcohol, and other multi-step total synthesis methods.
The existing methods have certain disadvantages, such as low selectivity of reaction area, low product yield, complicated product separation and purification process, difficult derivation and expansion of the route, and the like. Therefore, it is very important to develop a new synthesis method of resorcinol compounds or derivatives thereof, which is simpler, more efficient, lower in cost and suitable for industrial production. Meanwhile, the new method can meet the requirements of an ESH management system and meet the corresponding requirements on safety and environmental protection.
Disclosure of Invention
An object of the present invention is to provide a compound represented by the general formula II.
An object of the present invention is to provide a compound represented by the general formula III.
Still another object of the present invention is to provide a method for preparing a compound represented by formula II.
Still another object of the present invention is to provide a method for preparing a compound represented by the general formula III.
Still another object of the present invention is to provide a method for preparing a compound represented by formula IV.
Still another object of the present invention is to provide a method for preparing a compound represented by formula V.
According to one aspect of the present invention, there is provided a compound represented by formula II:
Figure BDA0002068876500000021
in the compound represented by the formula II, R1is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11OR-P (═ O) (OR)12)2。
Wherein the content of the first and second substances,
R4to R7And R11To R12Each independently hydrogen, substituted or unsubstituted C1-C20Linear or branched or cyclic alkyl, substituted or unsubstituted benzyl, substituted or unsubstituted C6-C20An aryl group;
at R4To R7And R11To R12Is substituted C1-C20Straight or branched chain or cyclic alkyl, substituted benzyl, or substituted C6-C20In the case of aryl, the substituent may be selected from cyano, nitro, amino, hydroxy, mercapto, halogen.
According to one aspect of the present invention, there is provided a compound represented by formula III:
Figure BDA0002068876500000022
in the compound represented by the formula III, R1is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11OR-P (═ O) (OR)12)2。
R2Each independently is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-SiR8R9R10、-C(＝O)-OR11、-P(＝O)(OR12)2、-CHR13(OR14)、C-R15(R16)(R17) Or a metal M.
R4To R14Each independently hydrogen, substituted or unsubstituted C1-C20Linear or branched or cyclic alkyl, substituted or unsubstituted benzyl, substitutedOr unsubstituted C6-C20An aryl group;
at R4To R14Is substituted C1-C20Straight or branched chain or cyclic alkyl, substituted benzyl, or substituted C6-C20In the case of aryl, the substituent may be selected from cyano, nitro, amino, hydroxy, mercapto, halogen.
R15、R16、R17Each independently selected from hydrogen, substituted or unsubstituted C1-C20Linear or branched or cyclic alkyl, C1-C20Linear or branched or cyclic alkyloxy, C1-C20Straight-chain or branched-chain or cyclic alkylcarbonyloxy, substituted siloxy, C1-C20Straight-chain or branched or cyclic alkylamino, C1-C20Straight or branched chain or cyclic alkylcarbonylamino, substituted or unsubstituted benzyl, substituted or unsubstituted C6-C20And (4) an aryl group.
At R15To R17Is substituted C1-C20Linear or branched or cyclic alkyl, substituted siloxy, substituted benzyl, or substituted C6-C20In the case of aryl, the substituent may be selected from cyano, nitro, amino, hydroxy, mercapto, halogen.
M may be selected from lithium, sodium, potassium, cesium, magnesium, calcium, or zinc.
According to an embodiment of the present invention, there is provided a method for preparing a compound represented by general formula II, including:
Figure BDA0002068876500000031
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1The reaction is carried out to obtain the compound shown in the formula II,
wherein R in the compound of formula II1Is defined and describedAs used herein, X is halogen.
Preferably, the reaction of the above step (2) is carried out under basic conditions, the alkali reagent is selected from one or more of lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, sodium phosphate, potassium phosphate, sodium monohydrogen phosphate, potassium monohydrogen phosphate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, triethylamine, diisopropylamine, diisopropylethylamine, tri-n-butylamine, pyridine, 2, 6-lutidine, p-dimethylaminopyridine, tetrahydropyrrole, morpholine, piperidine, 2,6, 6-tetramethylpiperidine, 1, 4-diazabicyclo [2.2.2] octane (DABCO), 1, 8-diazabicycloundecene-7-ene (DBU), quinoline, 2-methylquinoline and 8-hydroxyquinoline.
Preferably, the solvent used in the reaction of the step (2) is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether, C4-C12The compound is one or a mixture of more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, dichloromethane, chloroform, methyl tert-butyl ether, acetonitrile, acetone, N-dimethylformamide and dimethyl sulfoxide.
Preferably, in the step (2), the molar ratio of the compound of formula I, the esterification reagent and the alkali reagent is 1.05 (1.0-1.5) to (1.0-1.51), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, and the reaction time is 2-10 hours, more preferably 3-4 hours.
According to an embodiment of the present invention, there is provided a method for preparing a compound represented by general formula III, including:
Figure BDA0002068876500000032
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1The reaction is carried out to obtain the compound shown in the formula II,
(3) when R is2is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2When the compound of formula II is reacted with an esterifying reagent XR2Or R2OR2Reacting to obtain a compound shown in a formula III; when R is2is-SiR8R9R10、C-R15(R16)(R17) or-CHR13(OR14) When the compound of formula II is reacted with an esterifying reagent XR2Reacting to obtain a compound shown in a formula III; when R is2In the case of metal M, reacting the compound of formula II with a base reagent for metal M to obtain a compound of formula III,
wherein R1 in the compound of formula II and R in the compound of formula III1And R2Is as defined above, X is halogen,
wherein steps (1) and (2) are as described above,
preferably, in the step (3) above, when R is2is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2、-SiR8R9R10Or C-R15(R16)(R17) When the reaction of the above step (3) is carried out under basic conditions using a compound selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium phosphate, potassium phosphate, sodium hydrogen phosphate, potassium hydrogen phosphate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, triethylamine, diisopropylamine, diisopropylethylamine, tri-n-butylamine, pyridine, 2, 6-dimethylpyridine, p-dimethylaminopyridine, tetrahydropyrrole, morpholine, piperidine, 2,6, 6-tetramethylpiperidine, 1, 4-diazabicyclo [2.2.2] piperidine]One or a mixture of several of octane (DABCO), 1, 8-diazabicycloundecen-7-ene (DBU), quinoline, 2-methylquinoline and 8-hydroxyquinoline.
Preferably, the first and second electrodes are formed of a metal,in the above step (3), when R is2is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2、-SiR8R9R10Or C-R15(R16)(R17) In the case of (3), the solvent used in the reaction is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether and C4-C12The compound is one or a mixture of more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, dichloromethane, chloroform, methyl tert-butyl ether, acetonitrile, acetone, N-dimethylformamide and dimethyl sulfoxide.
Preferably, in the step (3) above, when R is2is-COR4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2、-SiR8R9R10Or C-R15(R16)(R17) In the case, the molar ratio of the compound of formula II, the esterification reagent and the alkali reagent is 1.0: 2.0-3.0, the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, and the reaction time is 2-10 hours, more preferably 3-4 hours.
Preferably, in the step (3) above, when R is2is-CHR13(OR14) When the reaction in the step (3) is carried out under an acidic condition, the used acidic reagent is one or a mixture of more of conventional inorganic protonic acid, organic carboxylic acid, organic sulfonic acid, organic phosphoric acid, organic Lewis acid and inorganic Lewis acid; more preferably, it includes hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydrofluoric acid, acetic acid, propionic acid, trifluoroacetic acid, malonic acid, benzoic acid, nitrobenzoic acid, methanesulfonic acid, p-toluenesulfonic acid, boron trifluoride, boron tribromide, boron trichloride, aluminum trichloride, ferric trichloride, zinc dichloride, indium trichloride, titanium tetrachloride.
Preferably, in the step (3) above, when R is2is-CHR13(OR14) In the case of (3), the solvent used in the reaction is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether and C4-C12The solvent is one or a mixture of more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, dichloromethane, chloroform, methyl tert-butyl ether, acetonitrile, acetone, N-dimethylformamide, dimethyl sulfoxide and water.
Preferably, in the step (3) above, when R is2is-CHR13(OR14) In the case, the molar ratio of the compound of formula II, the reaction reagent and the acidic reagent is 1.0: 2.0-3.0: 0.01-2.0, the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, and the reaction time is 2-10 hours, more preferably 3-4 hours.
Preferably, in the step (3) above, when R is2In the case of the metal M, the reaction in the step (3) is carried out in the presence of an alkali agent selected from lithium carbonate, lithium hydroxide, lithium tert-butoxide, n-butyllithium, and other alkyllithium or aryllithium agents, sodium carbonate, sodium bicarbonate, sodium hydroxide, sodium phosphate, sodium monohydrogen phosphate, sodium methoxide, sodium ethoxide, sodium isopropoxide, sodium tert-butoxide, potassium carbonate, potassium bicarbonate, potassium hydroxide, potassium phosphate, potassium monohydrogen phosphate, potassium methoxide, potassium ethoxide, potassium tert-butoxide, cesium carbonate, cesium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium phosphate, magnesium oxide, magnesium methoxide, magnesium ethoxide, magnesium isopropoxide, magnesium tert-butoxide, magnesium isopropoxide, and other Grignard reagents, calcium carbonate, calcium hydroxide, calcium phosphate, calcium oxide, calcium methoxide, calcium ethoxide, calcium isopropoxide, calcium tert-butoxide, zinc oxide, zinc ethoxide, zinc tert-butoxide, alkyl or aryl zinc agents.
Preferably, in the step (3) above, when R is2When the metal M is selected, the solvent used in the reaction of the step (3) is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether and C4-C12The solvent is one or a mixture of more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, methylene dichloride, methyl tert-butyl ether, N-dimethylformamide, dimethyl sulfoxide and water.
Preferably, the first and second electrodes are formed of a metal,in the above step (3), when R is2When the metal M is a metal, the molar ratio of the compound shown in the formula II to the esterification reagent to the alkali reagent is 1.0 (2.0-3.0) to (2.0-3.0), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, and the reaction time is 2-10 hours, more preferably 3-4 hours.
Preferably, steps (2) and (3) of the process may be carried out using a one-pot process.
According to an embodiment of the present invention, there is provided a method for preparing a compound represented by formula IV, the method including:
Figure BDA0002068876500000051
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1The reaction is carried out to obtain the compound shown in the formula II,
(3) when R is2is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2When the compound of formula II is reacted with an esterifying reagent XR2Or R2OR2Reacting to obtain a compound shown in a formula III; when R is2is-SiR8R9R10、C-R15(R16)(R17) or-CHR13(OR14) Reacting the compound of formula II with a reagent to obtain a compound of formula III; when R is2In the case of metal M, reacting the compound of formula II with a base reagent for metal M to obtain a compound of formula III,
(4) reacting the compound of formula III with a coupling reagent to obtain a compound of formula IV,
wherein the substituents of formula I to formula IV are the same as described above,
wherein the steps (1) to (3) are the same as described above,
preferably, the reaction in step (4) is carried out in the presence of a transition metal catalyst selected from the group consisting of palladium acetate, palladium dichloride, palladium on charcoal, bis (triphenylphosphine) palladium dichloride, tetrakis (triphenylphosphine) palladium, bis (tricyclohexylphosphine) palladium dichloride, [1,1 '-bis (diphenylphosphino) ferrocene ] palladium dichloride, [1, 2-bis (diphenylphosphino) ethane ] palladium dichloride, bis (di-tert-butylphosphine) palladium dichloride, tris [ dibenzylideneacetone ] dipalladium, bis [ dibenzylideneacetone ] palladium, 2-dicyclohexylphosphine-2', 6 '-dimethoxy-biphenyl with a palladium salt complex, 2-dicyclohexylphosphine-2', 6 '-diisopropoxy-biphenyl with a palladium salt complex, 2-dicyclohexylphosphine-2' -dimethylamino-biphenyl with a palladium salt complex, palladium chloride complex, palladium, A complex of 2-di-tert-butylphosphine biphenyl and palladium salt, a complex of 2-dicyclohexylphosphine-2 ',6' -dimethoxy-biphenyl and solid supported palladium, a complex of 2-dicyclohexylphosphine-2 ',6' -diisopropoxy-biphenyl and solid supported palladium, a complex of 2-dicyclohexylphosphine-2 ' -dimethylamino-biphenyl and solid supported palladium, a complex of 2-di-tert-butylphosphine biphenyl and solid supported palladium, ferric chloride, ferrous acetate, ferrous bromide, ferrous sulfate, ferric nitrate, tris (acetylacetone) iron, one or more of nickel salts and ligand complexes, wherein the nickel salt is selected from nickel difluoride, nickel dichloride, nickel dibromide, nickel diiodide, nickel acetate, nickel trifluoroacetate, nickel acetylacetonate, nickel bis (hexafluoroacetylacetone) and hydrates of the nickel salts, the ligand is selected from triphenylphosphine, tricyclohexylphosphine, tri-tert-butylphosphine, 1, 2-bis (diphenylphosphine) ethane, 1, 3-bis (diphenylphosphine) propane, 1 '-bis (diphenylphosphino) ferrocene, 2-dicyclohexylphosphine-2', 6 '-dimethoxybiphenyl, 2-dicyclohexylphosphine-2', 6 '-diisopropoxybiphenyl, 2-dicyclohexylphosphine-2' -dimethylamino-biphenyl, 2-di-tert-butylphosphine biphenyl, 2 '-bipyridine and 1, 10' -phenanthroline.
Preferably, the coupling reagent used in step (4) above is selected from the group consisting of a substituted alkyl lithium reagent, magnesium reagent, zinc reagent, or a complex salt thereof, and a substituted boronic acid or boronic ester compound, or a substituted trifluoroborate, or a substituted organotin reagent; more preferably, the coupling reagent comprises R3Magnesium chloride (R)3MgCl)、R3Magnesium bromide (R)3MgBr)、R3Magnesium iodide (R)3MgI)、R3Radical zinc chloride (R)3ZnCl)、R3Radical zinc bromide (R)3ZnCBr)、R3Zinc iodide (R)3ZnI)、R3Magnesium chloride-lithium chloride complex (R)3MgCl·LiCl)、R3Based magnesium bromide-lithium chloride complex (R)3MgBr·LiCl)、R3Based on magnesium iodide-lithium chloride complex (R)3MgI·LiCl)、R3Based on zinc chloride-lithium chloride complex (R)3ZnCl·LiCl)、R3Based zinc bromide-lithium chloride complex (R)3ZnBr·LiCl)、R3Based on zinc iodide-lithium chloride complex (R)3ZnI·LiCl)、R3Substituted boronic acids or esters, trialkylborons ((R)3)3B)、R3Substituted potassium fluoroborate (R)3BF3)、R3One or a mixture of several of substituted organotin.
Preferably, the solvent used in the reaction of step (4) is one or more selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether, benzene, toluene, xylene, acetonitrile, acetone, N-dimethylformamide, and dimethyl sulfoxide.
Preferably, in the step (4), the molar ratio of the compound of formula III, the transition metal catalyst and the coupling reagent is 1.0 (0.001-0.5): (0.8-2.0), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-100 ℃, more preferably-30 ℃, and the reaction time is 2-10 hours, more preferably 3-4 hours.
According to an embodiment of the present invention, there is provided a method for preparing a compound represented by formula V, the method including:
Figure BDA0002068876500000061
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1Reaction ofTo obtain the compound of the formula II,
(3) when R is2is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2When the compound of formula II is reacted with an esterifying reagent XR2Or R2OR2Reacting to obtain a compound shown in a formula III; when R is2is-SiR8R9R10、C-R15(R16)(R17) or-CHR13(OR14) When the compound of formula II is reacted with an esterifying reagent XR2Reacting to obtain a compound shown in a formula III; when R is2In the case of metal M, reacting the compound of formula II with a base reagent for metal M to obtain a compound of formula III,
(4) reacting the compound of formula III with a coupling reagent to obtain a compound of formula IV,
(5) and (3) carrying out a deprotection reaction on the compound of the formula IV to obtain the compound of the formula V.
Wherein the substituents of formula I to formula V are the same as described above,
wherein the steps (1) to (4) are the same as described above,
preferably, in the step (5) above, when R is2is-C (═ O) R4、-SiR8R9R10、-C(＝O)(OR11) In the process, the used reaction reagent is an alkaline reagent or an acidic reagent,
in the above step (5), when R is2is-SO2R5、-C(＝O)-NR6R7、-P(＝O)(OR12)2In the case of the method, the reaction reagent is only an alkaline reagent,
in the step (5), when R is2is-CHR13(OR14) Or C-R15(R16)(R17) In the case of the reaction, the reaction reagent used is only an acidic reagent,
wherein the basic reagent is selected from lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, magnesium carbonate, calcium carbonate, sodium bicarbonate, potassium bicarbonate, sodium phosphate, potassium phosphate, sodium monohydrogen phosphate, potassium monohydrogen phosphate, lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, tetrabutylammonium hydroxide, lithium methoxide, sodium methoxide, potassium methoxide, magnesium methoxide, sodium ethoxide, potassium ethoxide, magnesium ethoxide, lithium isopropoxide, sodium isopropoxide, potassium isopropoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, calcium oxide, magnesium oxide, sodium borohydride, potassium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride, sodium tri-sec-butylborohydride, potassium triisopropoxyborohydride, potassium tri-sec-butylborohydride, tetrabutylammonium fluoride, lithium fluoride, sodium fluoride, potassium fluoride, cesium fluoride, zinc fluoride, magnesium fluoride, sodium hydroxide, potassium hydroxide, sodium phosphate, potassium hydroxide, sodium hydroxide, One or a mixture of more of calcium fluoride.
Wherein the acidic reagent is selected from one or a mixture of more of conventional inorganic protonic acid, organic carboxylic acid, organic sulfonic acid, organic phosphoric acid, organic Lewis acid and inorganic Lewis acid; more preferably, it includes hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydrofluoric acid, acetic acid, propionic acid, trifluoroacetic acid, malonic acid, benzoic acid, nitrobenzoic acid, methanesulfonic acid, p-toluenesulfonic acid, boron trifluoride, boron tribromide, boron trichloride, aluminum trichloride, ferric trichloride, zinc dichloride, indium trichloride, titanium tetrachloride.
Preferably, the solvent used in the reaction of the step (5) is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether, C4-C12The solvent is one or a mixture of more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, dichloromethane, chloroform, methyl tert-butyl ether, methanol, ethanol, isopropanol, n-butanol, tert-butanol, glycol and water.
Preferably, in the step (5), the molar ratio of the compound of formula IV to the alkaline reagent or the acidic reagent is 1.0 (2.0-10.0), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, and the reaction time is 2-10 hours, more preferably 3-4 hours.
Preferably, steps (4) and (5) of the process may be carried out using a one-pot process.
According to an embodiment of the present invention, there is provided a method for preparing a compound represented by formula V, the method including:
Figure BDA0002068876500000071
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1The reaction is carried out to obtain the compound shown in the formula II,
(3') reacting the compound of formula II with a coupling reagent to obtain a compound of formula V,
wherein the substituents of formula I to formula II are the same as described above,
wherein the steps (1) to (2) are the same as described above,
preferably, the reaction in step (3 ') is carried out in the presence of a transition metal catalyst selected from the group consisting of palladium acetate, palladium dichloride, palladium on charcoal, bis (triphenylphosphine) palladium dichloride, tetrakis (triphenylphosphine) palladium, bis (tricyclohexylphosphine) palladium dichloride, [1,1 ' -bis (diphenylphosphino) ferrocene ] palladium dichloride, [1, 2-bis (diphenylphosphino) ethane ] palladium dichloride, bis (di-tert-butylphosphino) palladium dichloride, tris [ dibenzylideneacetone ] dipalladium, bis [ dibenzylideneacetone ] palladium, 2-dicyclohexylphosphine-2 ',6' -dimethoxy-biphenyl with a palladium salt complex, 2-dicyclohexylphosphine-2 ',6' -diisopropoxy-biphenyl with a palladium salt complex, 2-dicyclohexylphosphine-2 ' -dimethylamino-biphenyl with a palladium salt complex, palladium chloride, a complex of 2-di-tert-butylphosphine biphenyl and palladium salt, a complex of 2-dicyclohexylphosphine-2 ',6' -dimethoxy-biphenyl and solid supported palladium, a complex of 2-dicyclohexylphosphine-2 ',6' -diisopropoxy-biphenyl and solid supported palladium, a complex of 2-dicyclohexylphosphine-2 ' -dimethylamino-biphenyl and solid supported palladium, a complex of 2-di-tert-butylphosphine biphenyl and solid supported palladium, ferric chloride, ferrous acetate, ferrous bromide, ferrous sulfate, ferric nitrate, tris (acetylacetone) iron, one or more of nickel salts and ligand complexes, wherein the nickel salt is selected from nickel difluoride, nickel dichloride, nickel dibromide, nickel diiodide, nickel acetate, nickel trifluoroacetate, nickel acetylacetonate, nickel bis (hexafluoroacetylacetone) and hydrates of the nickel salts, the ligand is selected from triphenylphosphine, tricyclohexylphosphine, tri-tert-butylphosphine, 1, 2-bis (diphenylphosphine) ethane, 1, 3-bis (diphenylphosphine) propane, 1 '-bis (diphenylphosphino) ferrocene, 2-dicyclohexylphosphine-2', 6 '-dimethoxybiphenyl, 2-dicyclohexylphosphine-2', 6 '-diisopropoxybiphenyl, 2-dicyclohexylphosphine-2' -dimethylamino-biphenyl, 2-di-tert-butylphosphine biphenyl, 2 '-bipyridine and 1, 10' -phenanthroline.
Preferably, the coupling reagent used in step (3') above is selected from the group consisting of a substituted alkyl lithium reagent, a magnesium reagent, a zinc reagent, or a complex salt thereof, and a substituted boronic acid or boronic ester compound, or a substituted trifluoroborate, or a substituted organotin reagent; more preferably, the coupling reagent comprises R3Magnesium chloride, R3Magnesium bromide, R3Magnesium iodide, R3Zinc chloride, R3Zinc bromide, R3Zinc iodide, R3Based on magnesium chloride-lithium chloride complexes, R3Based magnesium bromide-lithium chloride complex, R3Based on magnesium iodide-lithium chloride complexes, R3Based zinc chloride-lithium chloride complex, R3Based zinc bromide-lithium chloride complex, R3Based zinc iodide-lithium chloride complex, R3Boric acid, R3Boric anhydride, R3Boronic acid pinacol ester, R3Boronic acid tert-amyl alcohol ester, R3Ethylene glycol boronate, R3Based on propylene glycol borate, tri R3Boron radical, R3Potassium trifluoroborate, R3Radical of tin trichloride or tetra R3One or a mixture of several of tin.
Preferably, the solvent used in the reaction of step (3') is one or more selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether, benzene, toluene, xylene, acetonitrile, acetone, N-dimethylformamide, and dimethyl sulfoxide.
Preferably, in the step (3'), the molar ratio of the compound of formula II, the transition metal catalyst and the coupling reagent is 1.0 (0.001-0.5) to (0.8-2.0), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, and the reaction time is 2-10 hours, more preferably 3-4 hours.
Preferably, the process is carried out using a one-pot process.
Advantageous effects
The invention takes industrial easily obtained chemicals or basic chemical raw material phloroglucinol as starting materials, prepares phloroglucinol derivatives through known condensation reaction and characteristic high-selectivity monoester reaction, and conveniently obtains resorcinol compounds or derivatives thereof with application significance through characteristic cross coupling reaction and the like, wherein the resorcinol compounds or the derivatives thereof comprise Cannabidiol (CBD) with pharmacological actions of epilepsy resistance, spasm resistance, anxiety resistance and the like, and derivatives, analogues, prodrug compounds and the like thereof.
In the synthetic route of the synthetic method, the terpene ring substituent segment, the aromatic ring segment containing diphenol hydroxyl and the terpene ring para-position substituent segment are synthesized and introduced into the final molecular structure step by step, and the synthetic method can be very simply and conveniently applied to the synthesis and preparation of other derivatives and analogues of cannabidiol. The method greatly improves the selectivity, avoids the generation of regioisomers and disubstituted by-products to the maximum extent, and obviously improves the yield. The method has the advantages of low material cost, less pollutants, simple and convenient operation, easy expanded application of a synthetic route and the like.
The method specifically designed in the invention can reduce byproducts, so the method can be carried out by using a one-pot method, thereby greatly reducing the product and energy consumption during purification by a step method and greatly reducing pollutants.
Detailed Description
Embodiments of the present invention are illustrated by the following examples. However, it is to be understood that embodiments of the invention are not limited to the specific details of the following examples, since other variations will be apparent to those of ordinary skill in the art in view of the present disclosure.
Example 1: preparation of Compound I-1
Figure BDA0002068876500000091
Phloroglucinol (50.4g, 400mmol) was added to a reaction flask with a constant pressure funnel. The air was removed under vacuum and replaced with nitrogen three times, the solvent tetrahydrofuran (150mL) was added and stirred until the solid dissolved clear. Then adding boron trifluoride-diethyl ether (2.85g, 20mmol) into the solution, uniformly stirring, and then cooling to-5 ℃. Then, a tetrahydrofuran (50mL) solution of trans-menthyl-2, 8-diene-1-ol (4.04g, 40mmol) was slowly dropped into the mixture from a constant pressure funnel with stirring at-5 to 5 ℃ and the reaction was maintained at-5 to 5 ℃ for 4 hours. The reaction was quenched by the addition of saturated aqueous sodium bicarbonate (20mL) and the reaction mixture was allowed to warm to 20-25 ℃ and stirred for half an hour. The aqueous phase is discarded after the liquid separation, the reaction mixture is concentrated by the organic phase vacuum distillation, and then the pure product of the orange yellow viscous oily substance is obtained by the separation and purification of silica gel column chromatography, wherein the yield is 83 percent.
1H NMR(CDCl3 400MHz):1.65(s,3H),1.71-1.80(m,5H),2.05-2.24(m,2H),2.34-2.40(m,1H),3.83-3.85(m,1H),4.50(s,1H),4.58(s,1H),5.51(s,1H),5.95(s,br,3H),6.19(s,br,2H).LR-MS(ESI)m/z:259(M-H)-,261(M+H)+.
Example 2: preparation of Compound II-1
Figure BDA0002068876500000092
Compound I-1(37.2g, 143mmol) and dichloromethane (80mL) were added to a reaction flask with a constant pressure funnel, 2, 6-lutidine (16.7g, 156mmol) was added and stirred well at room temperature. Trifluoromethanesulfonic anhydride (36.6g, 130mmol) and dichloromethane (80mL) were added to a constant pressure funnel and mixed well. Slowly dripping the trifluoromethanesulfonic anhydride solution into the reaction at the temperature of-20 to-15 ℃ under stirring, finishing the dripping within about 1 hour, heating the reaction to 0 to 5 ℃, and continuing the reaction for 3 to 4 hours. Heating the reaction mixture to room temperature of 20-25 ℃, adding dilute hydrochloric acid (1M, 35mL) while stirring to quench the reaction, and adjusting the pH value to 1-2. Fully stirring, standing, separating, and removing the water phase. The organic phase was washed once with water, then toluene (80mL) was added, concentrated by distillation under reduced pressure to remove most of the methylene chloride, and then slowly cooled to room temperature. Adding 2-3% potassium hydroxide aqueous solution (50mL) to fully wash the toluene phase twice, adding diluted hydrochloric acid (1M, 10mL) to wash the organic phase once, and adding water to wash the organic phase once. The organic phase was concentrated to remove most of toluene, and an oily solid residue was obtained, which was purified by silica gel column chromatography to obtain purified compound II-1 (43.3 g, 85% yield).
1H NMR(CDCl3,400MHz):1.65(s,3H),1.65-1.88(m,5H),2.10-2.25(m,2H),2.32-2.38(m,1H),3.86-3.89(m,1H),4.50(s,1H),4.65(s,1H),5.24(s,br,1H),5.54(s,1H),6.30(s,br,1H),6.36(s,br,2H).LR-MS(ESI)m/z:391(M-H)-,410(M+NH4)+.
Example 3: preparation of Compound III-1
Figure BDA0002068876500000101
Compound II-1(3.92g, 10mmol) and dichloromethane (10mL) were added to a reaction flask with a constant pressure funnel at room temperature and stirred until clear, and N, N-dimethylaminopyridine (122mg, 1mmol) and triethylamine (3.03g, 30mmol) were added and stirred until uniform. Pivaloyl chloride (3.01g, 25mmol) and dichloromethane (80mL) were added to a constant pressure funnel and mixed well. Slowly dropwise adding the pivaloyl chloride solution into the reaction under stirring at room temperature, finishing dropwise adding about 1 hour, and then continuously reacting for 10-12 hours at room temperature. Dilute hydrochloric acid (1M, 15mL) was added under stirring to quench the reaction and adjust the pH to 1-2. Fully stirring, standing, separating, and removing the water phase. The organic phase was washed once with saturated aqueous sodium bicarbonate (20mL) and once with additional water. The organic phase was concentrated to remove the solvent, giving crude compound III-1 as a clear, bright yellow oil, 5.3g, 95% yield.
1H NMR(CDCl3,400MHz):1.33-1.34(m,20H),1.53(s,3H),1.62(s,3H),1.66-2.12(m,5H),2.66-2.71(m,1H),3.59-3.61(m,1H),4.51(s,1H),4.55(s,1H),5.21(s,1H),6.79(s,2H).LR-MS(ESI)m/z:578(M+NH4)+.
Example 4: preparation of Compound IV-1
Figure BDA0002068876500000102
Anhydrous zinc chloride (102mg, 0.75mmol) was added to the reaction tube, dried under vacuum to remove water and oxygen, and purged with nitrogen. Anhydrous tetrahydrofuran (1mL) was added under nitrogen and stirred until clear. The n-amyl magnesium bromide solution (0.75mL, 1M, THF) was added dropwise to the zinc chloride solution at room temperature with stirring, and after dropping, the mixture was stirred at room temperature for 1 hour.
Compound III-1(280mg, 0.5mmol), Pd (dppf) as a catalyst, Cl2(3.7mg, 0.005mmol) and tetrahydrofuran (2mL) were added to the flask at room temperature and stirred until dissolved and clear, and replaced with nitrogen 3 times. And adding the prepared tetrahydrofuran solution of the n-amyl zinc chloride into the reaction at one time under stirring at room temperature, and then reacting at 50-55 ℃ for 3-4 hours. After the reaction was cooled to room temperature, saturated aqueous ammonium chloride (5mL) was added under stirring to quench the reaction, and ethyl acetate (5mL) was added for extraction. The aqueous phase was discarded by separation. The organic phase was concentrated to remove the solvent, to give a brown-yellow oily substance, which was purified by silica gel column chromatography to give a pure colorless transparent oily compound IV-1, 217mg, in a yield of 90%.
1H NMR(CDCl3,400MHz):0.88(t,J＝8Hz,3H),1.29-1.33(m,22H),1.54(s,3H),1.60(s,3H),1.54-1.80(m,4H),1.94-2.19(m,2H),2.52(t,J＝8Hz,2H),2.64-2.69(m,1H),3.50-3.53(m,1H),4.55(s,2H),5.25(s,1H),6.58(s,2H).LR-MS(ESI)m/z:500(M+NH4)+.
Example 5: preparation of Compound V-1
Figure BDA0002068876500000111
Compound IV-1(96mg, 0.2mmol), dichloromethane (4mL), methanol (0.5mL) and potassium hydroxide (56mg, 1mmol) were added to a reaction flask at room temperature, stirred until dissolved and clear, and replaced with nitrogen 3 times. And reacting for 10-12 hours at room temperature under stirring. The reaction was quenched by the addition of saturated aqueous ammonium chloride (5mL) and extracted by the addition of n-heptane (5mL) with thorough stirring. Standing, separating and discarding the water phase. The organic phase was concentrated to remove the solvent, to give a bright yellow oil, which was purified by silica gel column chromatography to give a pure product of compound V-1 as a bright yellow oil, 58mg, yield 91%.
1H NMR(CDCl3,400MHz):0.90(t,J＝8Hz,3H),1.22-1.33(m,7H),1.53-1.60(m,2H),1.65(s,3H),1.78(s,3H),2.00-2.21(m,2H),2.38-2.46(m,3H),3.89-3.92(m,1H),4.55(s,1H),4.66(s,1H),4.96(s,br,1H),5.57(s,1H),6.01(s,br,1H),6.20(s,br,2H).LR-MS(ESI)m/z:313(M-H)-,315(M+H)+.
Example 6: preparation of Compound II-2
Figure BDA0002068876500000112
Compound I-1(6.9g, 26.5mmol) and dichloromethane (20mL) were added to a reaction flask with a constant pressure funnel, triethylamine (2.95g, 29.0mmol) was added and stirred well at room temperature. P-toluenesulfonyl chloride (5.1g, 26.5mmol) and dichloromethane (20mL) were added to the constant pressure funnel and mixed well. Slowly dripping the solution of the p-toluenesulfonyl chloride into the reaction at the temperature of 0 +/-2 ℃ under stirring, finishing the dripping within about half an hour, and then heating the reaction to 20-25 ℃ to continue the reaction for 5 hours. Dilute hydrochloric acid (1M, 10mL) was added under stirring to quench the reaction and adjust the pH to 1-2. Fully stirring, standing, separating, and removing the water phase. Washing the organic phase once with saturated sodium bicarbonate aqueous solution, separating the solution to remove the aqueous phase, then washing once with water, concentrating the organic phase obtained by separating the solution by reduced pressure distillation to obtain oily solid residue, and separating and purifying the oily solid residue by silica gel column chromatography to obtain a compound II-2 pure product which is light yellow syrupy solid and has the yield of 9.5g and 87%.
1H NMR(CDCl3,400MHz):1.62(s,3H),1.73-1.87(m,8H),2.07-2.34(m,4H),2.43(s,3H),3.74-3.77(m,1H),3.83-3.85(m,1H),4.39(s,1H),4.58(s,1H),5.32(s,br,1H),5.50(s,1H),6.02(s,br,1H),6.14(s,br,2H),7.28(d,J＝8Hz,2H),7.69(d,J＝8Hz,2H).LR-MS(ESI)m/z:413(M-H)-,432(M+NH4)+.
Example 7: preparation of Compound V-1
Figure BDA0002068876500000121
Anhydrous zinc chloride (1.36g, 10.0mmol) and anhydrous lithium chloride (425mg, 10.0mmol) were added to the reaction tube, dried under vacuum to remove water and oxygen, and purged with nitrogen. Anhydrous tetrahydrofuran (5mL) was added under nitrogen and stirred until clear. The n-amyl magnesium bromide solution (10mL, 1M, THF) was added dropwise to the zinc chloride-lithium chloride solution at room temperature with stirring, and after dropping, the mixture was stirred at room temperature for 1 hour for further use.
Compound II-1(784mg, 2mmol), palladium acetate (4.5mg, 0.02mmol), 2-dicyclohexylphosphine-2 ',6' -dimethoxy-biphenyl (16.4mg, 0.04mmol) and tetrahydrofuran (3mL) were added to a reaction flask at room temperature and stirred until dissolved and clarified, and replaced with nitrogen 3 times. Transferring the prepared tetrahydrofuran solution of the n-amyl zinc chloride-lithium chloride by using an injector under the stirring at room temperature, slowly dropwise adding the tetrahydrofuran solution into the reaction, and then continuously reacting for 2-3 hours at the temperature of 25-30 ℃. The reaction was quenched by the addition of saturated aqueous ammonium chloride (10mL) with stirring at room temperature and extracted with ethyl acetate (5 mL). The aqueous phase was discarded by separation. The organic phase was concentrated to remove the solvent, to give a brown-yellow oily substance, which was purified by silica gel column chromatography to give a pure colorless transparent oily compound V-1, 217mg, in a yield of 30%.
1H NMR(CDCl3,400MHz):0.90(t,J＝8Hz,3H),1.22-1.33(m,7H),1.53-1.60(m,2H),1.65(s,3H),1.78(s,3H),2.00-2.21(m,2H),2.38-2.46(m,3H),3.89-3.92(m,1H),4.55(s,1H),4.66(s,1H),4.96(s,br,1H),5.57(s,1H),6.01(s,br,1H),6.20(s,br,2H).LR-MS(ESI)m/z:313(M-H)-,315(M+H)+.
Example 8: preparation of Compound III-2
Figure BDA0002068876500000122
Compound II-1(7.84g, 20mmol) and dichloromethane (50mL) were added to the reaction flask at room temperature and stirred until clear, and N, N-dimethylaminopyridine (244mg, 2mmol) and triethylamine (6.06g, 60mmol) were added and stirred until uniform. Slowly adding p-toluenesulfonyl chloride (9.53g, 50mmol) into the reaction in batches under stirring at room temperature, completing the addition for about 1 hour, and then continuing the reaction for 5-6 hours at room temperature. Dilute hydrochloric acid (1M, 15mL) was added under stirring to quench the reaction and adjust the pH to 1-2. Fully stirring, standing, separating, and removing the water phase. The organic phase was washed twice with saturated aqueous sodium bicarbonate (20mL) and once with additional water. The organic phase was concentrated to remove the solvent, yielding crude compound III-2 as a pale yellow oil, 113.7g, 98% yield.
1H NMR(CDCl3,400MHz):1.49(s,3H),1.54(s,3H),1.56-1.82(m,4H),2.40-2.45(m,1H),2.47(s,6H),3.59-3.62(m,1H),4.23(s,1H),4.41(s,1H),4.49(s,1H),7.06(s,br,2H),7.36(d,J＝8Hz,4H),7.75(d,J＝8Hz,4H).LR-MS(ESI)m/z:718(M+NH4)+.
Example 9: preparation of Compound IV-2
Figure BDA0002068876500000131
Anhydrous zinc chloride (210mg, 1.5mmol) was added to the reaction tube, dried under vacuum to remove water and oxygen, and purged with nitrogen. Anhydrous tetrahydrofuran (3mL) was added under nitrogen and stirred until clear. The n-amyl magnesium bromide solution (1.5mL, 1M, THF) was added dropwise to the zinc chloride solution at room temperature with stirring, and after dropping, the mixture was stirred at room temperature for 1 hour.
Compound III-2(700mg, 1mmol), Pd (dppf) as catalyst Cl2(7mg, 0.01mmol) and tetrahydrofuran (3mL) were added to the flask at room temperature and stirred until clear, and replaced with nitrogen 3 times. Stirring at room temperatureAnd adding the prepared tetrahydrofuran solution of the n-amyl zinc chloride into the reaction at one time under stirring, and then reacting for 3-4 hours at 50-55 ℃. After the reaction was cooled to room temperature, saturated aqueous ammonium chloride (10mL) was added under stirring to quench the reaction, and ethyl acetate (10mL) was added for extraction. The aqueous phase was discarded by separation. The organic phase was concentrated to remove the solvent to give a brown-yellow oil, which was purified by silica gel column chromatography to give a pale yellow pure compound IV-2, 490mg, 80% yield.
1H NMR(CDCl3,400MHz):0.90(t,J＝8Hz,3H),1.20-1.34(m,4H),1.44-1.58(m,11H),1.68-1.75(m,1H),2.39-2.48(m,9H),3.51-3.53(m,1H),4.31(s,1H),4.41(s,1H),4.51(s,1H),6.92(s,br,2H),7.33(d,J＝8Hz,4H),7.74(d,J＝8Hz,4H).LR-MS(ESI)m/z:640(M+NH4)+.
Example 10: preparation of Compound III-3
Figure BDA0002068876500000132
Compound II-1(500mg, 1.28mmol) and tetrahydrofuran (10mL) were added to the reaction flask at room temperature with stirring until clear, and N, N-dimethylaminopyridine (19mg, 0.13mmol) and diisopropylethylamine (495mg, 3.83mmol) were added with stirring. Di-tert-butyl dicarbonate (696mg, 3.19mmol) is slowly added into the reaction in batches under stirring at room temperature, the addition is completed by about half an hour, and then the reaction is continued for 5-6 hours at room temperature. Adding saturated ammonium chloride aqueous solution (20mL) under stirring to quench the reaction and adjusting the pH value to 5-6. Fully stirring, standing, separating, and removing the water phase. The organic phase was washed twice with additional water. The organic phase was concentrated to remove the solvent, yielding a crude off-white solid compound III-3, 644mg, in 85% yield.
1H NMR(CDCl3,400MHz):1.53(s,18H),1.59(s,3H),1.68(s,3H),1.72-1.80(m,2H),1.97-2.01(m,1H),2.19-2.26(m,1H),2.64-2.71(m,1H),3.72-3.74(m,1H),4.40(s,1H),4.51(s,1H),5.18(s,1H),6.98(s,2H).LR-MS(ESI)m/z:610(M+NH4)+.
Example 11: preparation of Compound III-3 (continuous feed)
Figure BDA0002068876500000133
Compound I-1(260mg, 1mmol) and toluene (3mL) were added to a reaction flask with a constant pressure funnel, 2, 6-lutidine (128mg, 0.12mmol) was added and stirred well at room temperature. Trifluoromethanesulfonic anhydride (282mg, 1mmol) was added to a constant pressure funnel. Slowly dripping the trifluoromethanesulfonic anhydride solution into the reaction at a temperature of between 25 ℃ below zero and 20 ℃ below zero while stirring, finishing the dripping within about 1 hour, heating the reaction to 0-5 ℃, and continuing the reaction for 3-4 hours. The reaction mixture is warmed up to room temperature (20-25 ℃), diluted hydrochloric acid (1M, 3mL) is added under stirring to quench the reaction and the pH value is adjusted to 1-2. Fully stirring, standing, separating, and removing the water phase. Adding 10-15% potassium carbonate aqueous solution (5mL) to fully wash the toluene phase, standing, separating, and discarding the water phase. N, N-dimethylaminopyridine (12.2mg, 0.1mmol) and potassium carbonate (345mg, 2.5mmol) and acetonitrile (1mL) were added to the organic phase and stirred well. Di-tert-butyl dicarbonate (490mg, 2.25mmol) is slowly added to the reaction in portions under stirring at room temperature, the addition is completed in about half an hour, and then the reaction is continued for 5-6 hours at room temperature. Adding 10mL of water to quench the reaction, fully stirring, standing, separating liquid and removing a water phase. The organic phase was concentrated to remove most of toluene to obtain an oily solid residue, which was purified by silica gel column chromatography to obtain 520mg of pure compound III-3 with a yield of 88%.
1H NMR(CDCl3,400MHz):1.53(s,18H),1.59(s,3H),1.68(s,3H),1.72-1.80(m,2H),1.97-2.01(m,1H),2.19-2.26(m,1H),2.64-2.71(m,1H),3.72-3.74(m,1H),4.40(s,1H),4.51(s,1H),5.18(s,1H),6.98(s,2H).LR-MS(ESI)m/z:610(M+NH4)+.
Example 12: preparation of Compound V-1 (continuous feed)
Figure BDA0002068876500000141
Will have no effect onZinc chloride hydrate (100mg, 0.75mmol) and anhydrous lithium chloride (33mg, 0.75mmol) were added to the reaction tube, dried under vacuum to remove water and oxygen, and nitrogen was introduced to protect. Anhydrous tetrahydrofuran (2mL) was added under nitrogen and stirred until clear. The n-amyl magnesium bromide solution (0.75mL, 1M, THF) was added dropwise to the zinc chloride solution at room temperature with stirring, and the mixture was stirred at room temperature for 0.5 hour until completely dissolved and clear. Compound III-3(300mg, 0.5mmol), Pd (dppf) as a catalyst, Cl2(4mg, 0.005mmol) is added into the zinc reagent solution under the protection of nitrogen flow under stirring at room temperature, and then the mixture reacts for 3-4 hours at 55-60 ℃. After the reaction was cooled to room temperature, saturated aqueous ammonium chloride (5mL) was added under stirring to quench the reaction, and toluene (3mL) was added for extraction. Fully stirring, standing for layering, separating liquid and removing water phase. Saturated aqueous sodium bicarbonate (5mL) was added to the organic phase, the mixture was allowed to stand for layer separation, and the aqueous phase was discarded. The organic phase was concentrated to remove the solvent, then methanol (5mL) and potassium hydroxide (140mg, 2.5mmol) were added, stirred until dissolved clear, and replaced with nitrogen 3 times. Reacting for 4-5 hours at reflux temperature. After cooling to room temperature, adding n-heptane (5mL) and saturated ammonium chloride aqueous solution (5mL) to quench the reaction, and adjusting the pH value to 4-5. Fully stirring, standing, separating liquid and removing a water phase. The organic phase was concentrated to remove the solvent, and purified by silica gel column chromatography to give pure compound V-1 as a bright yellow oil in a yield of 86% at 135 mg.
1H NMR(CDCl3,400MHz):0.90(t,J＝8Hz,3H),1.22-1.33(m,7H),1.53-1.60(m,2H),1.65(s,3H),1.78(s,3H),2.00-2.21(m,2H),2.38-2.46(m,3H),3.89-3.92(m,1H),4.55(s,1H),4.66(s,1H),4.96(s,br,1H),5.57(s,1H),6.01(s,br,1H),6.20(s,br,2H).LR-MS(ESI)m/z:313(M-H)-,315(M+H)+。

Claims (7)

1. A compound represented by the general formula II:
Figure FDA0002068876490000011
in the compound represented by the formula II, R1is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11OR-P (═ O) (OR)12)2，
Wherein the content of the first and second substances,
R4to R7And R11To R12Each independently hydrogen, substituted or unsubstituted C1-C20Linear or branched or cyclic alkyl, substituted or unsubstituted benzyl, substituted or unsubstituted C6-C20An aryl group;
at R4To R7And R11To R12Is substituted C1-C20Straight or branched chain or cyclic alkyl, substituted benzyl, or substituted C6-C20In the case of aryl, the substituents are selected from cyano, nitro, amino, hydroxy, mercapto, halogen.
2. A compound represented by the general formula III:
Figure FDA0002068876490000012
in the compound represented by the formula III, R1is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11OR-P (═ O) (OR)12)2，
R2Each independently is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-SiR8R9R10、-C(＝O)-OR11、-P(＝O)(OR12)2、-CHR13(OR14)、C-R15(R16)(R17) Or a metal M,
R4to R14Each independently hydrogen, substituted or unsubstituted C1-C20Linear or branched or cyclic alkyl, substituted or unsubstituted benzyl, substituted or unsubstituted C6-C20An aryl group;
at R4To R14Is substituted C1-C20Straight or branched chain or cyclic alkyl, substituted benzyl, or substituted C6-C20In the case of aryl, the substituents are selected from cyano, nitro, amino, hydroxy, mercapto, halogen,
R15、R16、R17each independently selected from hydrogen, substituted or unsubstituted C1-C20Linear or branched or cyclic alkyl, C1-C20Linear or branched or cyclic alkyloxy, C1-C20Straight-chain or branched-chain or cyclic alkylcarbonyloxy, substituted siloxy, C1-C20Straight-chain or branched or cyclic alkylamino, C1-C20Straight or branched chain or cyclic alkylcarbonylamino, substituted or unsubstituted benzyl, substituted or unsubstituted C6-C20An aryl group, a heteroaryl group,
at R15To R17Is substituted C1-C20Linear or branched or cyclic alkyl, substituted siloxy, substituted benzyl, or substituted C6-C20In the case of aryl, the substituents are selected from cyano, nitro, amino, hydroxy, mercapto, halogen,
m is selected from lithium, sodium, potassium, cesium, magnesium, calcium, or zinc.
3. A method of preparing a compound represented by formula II, the method comprising:
Figure FDA0002068876490000021
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1The reaction is carried out to obtain the compound shown in the formula II,
wherein R in the compound of formula II1Is defined as in claim 11Is as defined above, X is halogen,
preferably, the reaction of step (2) is carried out under basic conditions, and the used basic reagent is one or more selected from lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, sodium phosphate, potassium phosphate, sodium monohydrogen phosphate, potassium monohydrogen phosphate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, triethylamine, diisopropylamine, diisopropylethylamine, tri-n-butylamine, pyridine, 2, 6-dimethylpyridine, p-dimethylaminopyridine, tetrahydropyrrole, morpholine, piperidine, 2,6, 6-tetramethylpiperidine, 1, 4-diazabicyclo [2.2.2] octane (DABCO), 1, 8-diazabicycloundec-7-ene (DBU), quinoline, 2-methylquinoline, and 8-hydroxyquinoline,
preferably, the solvent used in the reaction of the step (2) is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether, C4-C12One or a mixture of more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, dichloromethane, chloroform, methyl tert-butyl ether, acetonitrile, acetone, N-dimethylformamide and dimethyl sulfoxide,
preferably, in the step (2), the molar ratio of the compound of formula I, the esterification reagent and the alkali reagent is 1.05 (1.0-1.5) to (1.0-1.51), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, and the reaction time is 2-10 hours, more preferably 3-4 hours.
4. A method of preparing a compound represented by formula III, the method comprising:
Figure FDA0002068876490000022
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1The reaction is carried out to obtain the compound shown in the formula II,
(3) when R is2is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2When the compound of formula II is reacted with an esterifying reagent XR2Or R2OR2Reacting to obtain a compound shown in a formula III; when R is2is-SiR8R9R10、C-R15(R16)(R17) or-CHR13(OR14) When the compound of formula II is reacted with an esterifying reagent XR2Reacting to obtain a compound shown in a formula III; when R is2In the case of metal M, reacting the compound of formula II with a base reagent for metal M to obtain a compound of formula III,
wherein R in the compound of formula II1Definition of (1), R in the compound of the formula III1And R2Is defined as in claim 21And R2Is as defined above, X is halogen,
wherein steps (1) and (2) are the same as steps (1) and (2) in claim 5,
preferably, in the step (3) above, when R is2is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2、-SiR8R9R10Or C-R15(R16)(R17) When the reaction of the above step (3) is carried out under basic conditions using a compound selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium phosphate, potassium phosphate, sodium hydrogen phosphate, potassium hydrogen phosphate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, triethylamine, diisopropylamine, diisopropylethylamine, tri-n-butylamine, pyridine, 2, 6-dimethylpyridine, p-dimethylaminopyridine, tetrahydropyrrole, morpholine, piperidine, 2,6, 6-tetramethylpiperidine, 1, 4-diazabicyclo [2.2.2] piperidine]One or a mixture of several of octane (DABCO), 1, 8-diazabicycloundecen-7-ene (DBU), quinoline, 2-methylquinoline and 8-hydroxyquinoline,
preferably, in the step (3) above, when R is2is-COR4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2、-SiR8R9R10Or C-R15(R16)(R17) In the case of (3), the solvent used in the reaction is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether and C4-C12One or a mixture of more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, dichloromethane, chloroform, methyl tert-butyl ether, acetonitrile, acetone, N-dimethylformamide and dimethyl sulfoxide,
preferably, in the step (3) above, when R is2is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2、-SiR8R9R10Or C-R15(R16)(R17) In the case, the molar ratio of the compound of formula II, the esterification reagent and the alkali reagent is 1.0: 2.0-3.0, the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, the reaction time is 2-10 hours, more preferably 3-4 hours,
preferably, in the step (3) above, when R is2is-CHR13(OR14) When the reaction in the step (3) is carried out under an acidic condition, the used acidic reagent is one or a mixture of more of conventional inorganic protonic acid, organic carboxylic acid, organic sulfonic acid, organic phosphoric acid, organic Lewis acid and inorganic Lewis acid; more preferably, it includes hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydrofluoric acid, acetic acid, propionic acid, trifluoroacetic acid, malonic acid, benzoic acid, nitrobenzoic acid, methanesulfonic acid, p-toluenesulfonic acid, boron trifluoride, boron tribromide, boron trichloride, aluminum trichloride, ferric trichloride, zinc dichloride, indium trichloride, titanium tetrachloride,
preferably, in the step (3) above, when R is2is-CHR13(OR14) In the case of (3), the solvent used in the reaction is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether and C4-C12One or a mixture of more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, dichloromethane, chloroform, methyl tert-butyl ether, acetonitrile, acetone, N-dimethylformamide, dimethyl sulfoxide and water,
preferably, in the step (3) above, when R is2is-CHR13(OR14) In the case, the molar ratio of the compound of formula II, the reaction reagent and the acidic reagent is 1.0: 2.0-3.0: 0.01-2.0, the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, the reaction time is 2-10 hours, more preferably 3-4 hours,
preferably, in the step (3) above, when R is2In the case of the metal M, the reaction in the step (3) is carried out in the presence of an alkali agent selected from lithium carbonate, lithium hydroxide, lithium tert-butoxide, n-butyllithium, and other alkyllithium or aryllithium agents, sodium carbonate, sodium bicarbonate, sodium hydroxide, sodium phosphate, sodium monohydrogen phosphate, sodium methoxide, sodium ethoxide, sodium isopropoxide, sodium tert-butoxide, potassium carbonate, potassium bicarbonate, potassium hydroxide, potassium phosphate, potassium monohydrogen phosphate, potassium methoxide, potassium ethoxide, potassium tert-butoxide, cesium carbonate, cesium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium phosphate, magnesium oxide, magnesium methoxide, magnesium ethoxide, magnesium isopropoxide, magnesium tert-butoxide, magnesium isopropoxide, and other Grignard reagents, calcium carbonate, calcium hydroxide, calcium phosphate, calcium oxide, calcium methoxide, calcium ethoxide, calcium isopropoxide, calcium tert-butoxide, zinc oxide, zinc ethoxide, zinc tert-butoxide, alkyl or aryl zinc agents,
preferably, in the step (3) above, when R is2When the metal M is selected, the solvent used in the reaction of the step (3) is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether and C4-C12One or a mixture of more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, methylene dichloride, methyl tert-butyl ether, N-dimethylformamide, dimethyl sulfoxide and water,
preferably, in the step (3) above, when R is2When the metal M is a metal, the molar ratio of the compound shown in the formula II to the esterification reagent to the alkali reagent is 1.0 (2.0-3.0) to (2.0-3.0), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, the reaction time is 2-10 hours, more preferably 3-4 hours,
preferably, steps (2) and (3) of the process are carried out using a one-pot process.
5. A process for preparing a compound represented by formula IV, comprising:
Figure FDA0002068876490000041
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1The reaction is carried out to obtain the compound shown in the formula II,
(3) when R is2is-C (═ O) R4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2When the compound of formula II is reacted with an esterifying reagent XR2Or R2OR2Reacting to obtain a compound shown in a formula III; when R is2is-SiR8R9R10、C-R15(R16)(R17) or-CHR13(OR14) Reacting the compound of formula II with a reagent to obtain a compound of formula III; when R is2In the case of metal M, reacting the compound of formula II with a base reagent for metal M to obtain a compound of formula III,
(4) reacting the compound of formula III with a coupling reagent to obtain a compound of formula IV,
wherein the substituents of the formulae I to IV are as defined in claim 3,
wherein steps (1) to (3) are the same as the corresponding steps described in claim 6,
preferably, the reaction in step (4) is carried out in the presence of a transition metal catalyst selected from the group consisting of palladium acetate, palladium dichloride, palladium on charcoal, bis (triphenylphosphine) palladium dichloride, tetrakis (triphenylphosphine) palladium, bis (tricyclohexylphosphine) palladium dichloride, [1,1 '-bis (diphenylphosphino) ferrocene ] palladium dichloride, [1, 2-bis (diphenylphosphino) ethane ] palladium dichloride, bis (di-tert-butylphosphine) palladium dichloride, tris [ dibenzylideneacetone ] dipalladium, bis [ dibenzylideneacetone ] palladium, 2-dicyclohexylphosphine-2', 6 '-dimethoxy-biphenyl with a palladium salt complex, 2-dicyclohexylphosphine-2', 6 '-diisopropoxy-biphenyl with a palladium salt complex, 2-dicyclohexylphosphine-2' -dimethylamino-biphenyl with a palladium salt complex, palladium chloride complex, palladium, A complex of 2-di-tert-butylphosphine biphenyl and palladium salt, a complex of 2-dicyclohexylphosphine-2 ',6' -dimethoxy-biphenyl and solid supported palladium, a complex of 2-dicyclohexylphosphine-2 ',6' -diisopropoxy-biphenyl and solid supported palladium, a complex of 2-dicyclohexylphosphine-2 ' -dimethylamino-biphenyl and solid supported palladium, a complex of 2-di-tert-butylphosphine biphenyl and solid supported palladium, ferric chloride, ferrous acetate, ferrous bromide, ferrous sulfate, ferric nitrate, tris (acetylacetone) iron, one or more of nickel salts and ligand complexes, wherein the nickel salt is selected from nickel difluoride, nickel dichloride, nickel dibromide, nickel diiodide, nickel acetate, nickel trifluoroacetate, nickel acetylacetonate, nickel bis (hexafluoroacetylacetone) and hydrates of the nickel salts, the ligand is selected from triphenylphosphine, tricyclohexylphosphine, tri-tert-butylphosphine, 1, 2-bis (diphenylphosphine) ethane, 1, 3-bis (diphenylphosphine) propane, 1 '-bis (diphenylphosphino) ferrocene, 2-dicyclohexylphosphine-2', 6 '-dimethoxybiphenyl, 2-dicyclohexylphosphine-2', 6 '-diisopropoxybiphenyl, 2-dicyclohexylphosphine-2' -dimethylamino-biphenyl, 2-di-tert-butylphosphine biphenyl, 2 '-bipyridine, 1, 10' -phenanthroline,
preferably, the coupling reagent used in step (4) above is selected from the group consisting of a substituted alkyl lithium reagent, magnesium reagent, zinc reagent, or a complex salt thereof, and a substituted boronic acid or boronic ester compound, or a substituted trifluoroborate, or a substituted organotin reagent; more preferably, the coupling reagent comprises R3Magnesium chloride, R3Magnesium bromide, R3Magnesium iodide, R3Zinc chloride, R3Zinc bromide, R3Zinc iodide, R3Based on magnesium chloride-lithium chloride complexes, R3Based magnesium bromide-lithium chloride complex, R3Based on magnesium iodide-lithium chloride complexes, R3Based zinc chloride-lithium chloride complex, R3Based zinc bromide-lithium chloride complex, R3Based zinc iodide-lithium chloride complex, R3Substituted boronic acids or esters, trialkylborons, R3Substituted potassium fluoroborate, R3One or a mixture of several of substituted organotin,
preferably, the solvent used in the reaction of step (4) is one or more selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether, benzene, toluene, xylene, acetonitrile, acetone, N-dimethylformamide and dimethyl sulfoxide,
preferably, in the step (4), the molar ratio of the compound of formula III, the transition metal catalyst and the coupling reagent is 1.0 (0.001-0.5): (0.8-2.0), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-100 ℃, more preferably-30 ℃, and the reaction time is 2-10 hours, more preferably 3-4 hours.
6. A process for preparing a compound represented by formula V, the process comprising:
Figure FDA0002068876490000051
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1The reaction is carried out to obtain the compound shown in the formula II,
(3) when R is2is-COR4、-SO2R5、-C(＝O)-NR6R7、-C(＝O)-OR11、-P(＝O)(OR12)2When, a compound of formula IIWith esterifying reagents XR2Or R2OR2Reacting to obtain a compound shown in a formula III; when R is2is-SiR8R9R10、C-R15(R16)(R17) or-CHR13(OR14) When the compound of formula II is reacted with an esterifying reagent XR2Reacting to obtain a compound shown in a formula III; when R is2In the case of metal M, reacting the compound of formula II with a base reagent for metal M to obtain a compound of formula III,
(4) reacting the compound of formula III with a coupling reagent to obtain a compound of formula IV,
(5) the compound of formula IV is subjected to a deprotection reaction to obtain a compound of formula V,
wherein the substituents of the formulae I to V are the same as those described in claim 4,
wherein steps (1) to (4) are the same as those described in claim 7,
preferably, in the step (5) above, when R is2is-C (═ O) R4、-SiR8R9R10、-C(＝O)(OR11) In the process, the used reaction reagent is an alkaline reagent or an acidic reagent,
in the above step (5), when R is2is-SO2R5、-C(＝O)-NR6R7、-P(＝O)(OR12)2In the case of the method, the reaction reagent is only an alkaline reagent,
in the step (5), when R is2is-CHR13(OR14) Or C-R15(R16)(R17) In the case of the reaction, the reaction reagent used is only an acidic reagent,
wherein the basic reagent is selected from lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, magnesium carbonate, calcium carbonate, sodium bicarbonate, potassium bicarbonate, sodium phosphate, potassium phosphate, sodium monohydrogen phosphate, potassium monohydrogen phosphate, lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, tetrabutylammonium hydroxide, lithium methoxide, sodium methoxide, potassium methoxide, magnesium methoxide, sodium ethoxide, potassium ethoxide, magnesium ethoxide, lithium isopropoxide, sodium isopropoxide, potassium isopropoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, calcium oxide, magnesium oxide, sodium borohydride, potassium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride, sodium tri-sec-butylborohydride, potassium triisopropoxyborohydride, potassium tri-sec-butylborohydride, tetrabutylammonium fluoride, lithium fluoride, sodium fluoride, potassium fluoride, cesium fluoride, zinc fluoride, magnesium fluoride, sodium hydroxide, potassium hydroxide, sodium phosphate, potassium hydroxide, sodium hydroxide, One or a mixture of more of calcium fluoride,
wherein the acidic reagent is selected from one or a mixture of more of conventional inorganic protonic acid, organic carboxylic acid, organic sulfonic acid, organic phosphoric acid, organic Lewis acid and inorganic Lewis acid; more preferably, it includes hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydrofluoric acid, acetic acid, propionic acid, trifluoroacetic acid, malonic acid, benzoic acid, nitrobenzoic acid, methanesulfonic acid, p-toluenesulfonic acid, boron trifluoride, boron tribromide, boron trichloride, aluminum trichloride, ferric trichloride, zinc dichloride, indium trichloride, titanium tetrachloride,
preferably, the solvent used in the reaction of the step (5) is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether, C4-C12One or more of straight chain or branched chain or cyclic alkane, benzene, toluene, xylene, dichloromethane, chloroform, methyl tert-butyl ether, methanol, ethanol, isopropanol, n-butanol, tert-butanol, ethylene glycol and water,
preferably, in the step (5), the molar ratio of the compound of formula IV to the alkaline reagent or the acidic reagent is 1.0 (2.0-10.0), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, the reaction time is 2-10 hours, more preferably 3-4 hours,
preferably, steps (4) and (5) of the process may be carried out using a one-pot process.
7. A process for preparing a compound represented by formula V, the process comprising:
Figure FDA0002068876490000061
(1) phloroglucinol is subjected to condensation reaction with trans-menthyl-2, 8-diene-1-ol to obtain a compound shown in a formula I,
(2) a compound of formula I with an esterifying reagent XR1Or R1OR1The reaction is carried out to obtain the compound shown in the formula II,
(3') reacting the compound of formula II with a coupling reagent to obtain a compound of formula V,
wherein the substituents of the formulae I to II are the same as those described in claim 4,
wherein the steps (1) to (2) are the same as those described in claim 5,
preferably, the reaction in step (3 ') is carried out in the presence of a transition metal catalyst selected from the group consisting of palladium acetate, palladium dichloride, palladium on charcoal, bis (triphenylphosphine) palladium dichloride, tetrakis (triphenylphosphine) palladium, bis (tricyclohexylphosphine) palladium dichloride, [1,1 ' -bis (diphenylphosphino) ferrocene ] palladium dichloride, [1, 2-bis (diphenylphosphino) ethane ] palladium dichloride, bis (di-tert-butylphosphino) palladium dichloride, tris [ dibenzylideneacetone ] dipalladium, bis [ dibenzylideneacetone ] palladium, 2-dicyclohexylphosphine-2 ',6' -dimethoxy-biphenyl with a palladium salt complex, 2-dicyclohexylphosphine-2 ',6' -diisopropoxy-biphenyl with a palladium salt complex, 2-dicyclohexylphosphine-2 ' -dimethylamino-biphenyl with a palladium salt complex, palladium chloride, a complex of 2-di-tert-butylphosphine biphenyl and palladium salt, a complex of 2-dicyclohexylphosphine-2 ',6' -dimethoxy-biphenyl and solid supported palladium, a complex of 2-dicyclohexylphosphine-2 ',6' -diisopropoxy-biphenyl and solid supported palladium, a complex of 2-dicyclohexylphosphine-2 ' -dimethylamino-biphenyl and solid supported palladium, a complex of 2-di-tert-butylphosphine biphenyl and solid supported palladium, ferric chloride, ferrous acetate, ferrous bromide, ferrous sulfate, ferric nitrate, tris (acetylacetone) iron, one or more of nickel salts and ligand complexes, wherein the nickel salt is selected from nickel difluoride, nickel dichloride, nickel dibromide, nickel diiodide, nickel acetate, nickel trifluoroacetate, nickel acetylacetonate, nickel bis (hexafluoroacetylacetone) and hydrates of the nickel salts, the ligand is selected from triphenylphosphine, tricyclohexylphosphine, tri-tert-butylphosphine, 1, 2-bis (diphenylphosphine) ethane, 1, 3-bis (diphenylphosphine) propane, 1 '-bis (diphenylphosphino) ferrocene, 2-dicyclohexylphosphine-2', 6 '-dimethoxybiphenyl, 2-dicyclohexylphosphine-2', 6 '-diisopropoxybiphenyl, 2-dicyclohexylphosphine-2' -dimethylamino-biphenyl, 2-di-tert-butylphosphine biphenyl, 2 '-bipyridine, 1, 10' -phenanthroline,
preferably, the coupling reagent used in step (3') above is selected from the group consisting of a substituted alkyl lithium reagent, a magnesium reagent, a zinc reagent, or a complex salt thereof, and a substituted boronic acid or boronic ester compound, or a substituted trifluoroborate, or a substituted organotin reagent; more preferably, the coupling reagent comprises R3Magnesium chloride, R3Magnesium bromide, R3Magnesium iodide, R3Zinc chloride, R3Zinc bromide, R3Zinc iodide, R3Based on magnesium chloride-lithium chloride complexes, R3Based magnesium bromide-lithium chloride complex, R3Based on magnesium iodide-lithium chloride complexes, R3Based zinc chloride-lithium chloride complex, R3Based zinc bromide-lithium chloride complex, R3Based zinc iodide-lithium chloride complex, R3Boric acid, R3Boric anhydride, R3Boronic acid pinacol ester, R3Boronic acid tert-amyl alcohol ester, R3Ethylene glycol boronate, R3Based on propylene glycol borate, tri R3Boron radical, R3Potassium trifluoroborate, R3Radical of tin trichloride or tetra R3One or a mixture of several of tin bases,
preferably, the solvent used in the reaction of step (3') is one or more selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, ethylene glycol dimethyl ether, benzene, toluene, xylene, acetonitrile, acetone, N-dimethylformamide, and dimethyl sulfoxide,
preferably, in the step (3'), the molar ratio of the compound of formula II, the transition metal catalyst and the coupling reagent is 1.0 (0.001-0.5) to (0.8-2.0), the concentration of the solution is 0.05-2.0 mol/L, the reaction temperature is-60-30 ℃, more preferably-30-10 ℃, the reaction time is 2-10 hours, more preferably 3-4 hours,
preferably, the process is carried out using a one-pot process.
CN201910430644.7A 2019-05-22 2019-05-22 Meta-benzene polyphenol derivative and preparation method thereof Active CN112062697B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910430644.7A CN112062697B (en) 2019-05-22 2019-05-22 Meta-benzene polyphenol derivative and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910430644.7A CN112062697B (en) 2019-05-22 2019-05-22 Meta-benzene polyphenol derivative and preparation method thereof

Publications (2)

Publication Number Publication Date
CN112062697A true CN112062697A (en) 2020-12-11
CN112062697B CN112062697B (en) 2023-09-01

Family

ID=73657849

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910430644.7A Active CN112062697B (en) 2019-05-22 2019-05-22 Meta-benzene polyphenol derivative and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112062697B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113735709A (en) * 2021-09-17 2021-12-03 中国农业科学院农产品加工研究所 Cannabidiol-2-butyrate and application thereof
CN114269717A (en) * 2019-05-23 2022-04-01 凯尔化学科技公司 Catalytic cannabinoid processes and precursors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166727A1 (en) * 2000-06-16 2003-09-04 Raphael Mechoulam Pharmaceutical compositions comprising cannabidiol derivatives
US20070072939A1 (en) * 2005-06-16 2007-03-29 Euro-Celtique, S.A. Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2011006099A1 (en) * 2009-07-10 2011-01-13 Northeastern University Angiogenic resorcinol derivatives
CN106810426A (en) * 2016-12-29 2017-06-09 暨明医药科技（苏州）有限公司 A kind of synthetic method of cannabidiol
US20170349518A1 (en) * 2016-06-01 2017-12-07 Daniel Dickman Crystalline Form of Cannabidiol
US20190023680A1 (en) * 2017-07-21 2019-01-24 University Of South Florida Synthesis of cannabinoids

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166727A1 (en) * 2000-06-16 2003-09-04 Raphael Mechoulam Pharmaceutical compositions comprising cannabidiol derivatives
US20070072939A1 (en) * 2005-06-16 2007-03-29 Euro-Celtique, S.A. Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2011006099A1 (en) * 2009-07-10 2011-01-13 Northeastern University Angiogenic resorcinol derivatives
US20120172339A1 (en) * 2009-07-10 2012-07-05 Northeastern University Angiogenic resorcinol derivatives
US20170349518A1 (en) * 2016-06-01 2017-12-07 Daniel Dickman Crystalline Form of Cannabidiol
CN106810426A (en) * 2016-12-29 2017-06-09 暨明医药科技（苏州）有限公司 A kind of synthetic method of cannabidiol
US20190023680A1 (en) * 2017-07-21 2019-01-24 University Of South Florida Synthesis of cannabinoids

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RAPHAEL MECHOULAM等: "Syntheses of Δ1-Tetrahydrocannabinol and Related Cannabinoids", 《J. AM. CHEM. SOC.》 *
XUDONG GONG等: "Synthesis of CBD and Its Derivatives Bearing Various C4′-Side Chains with a Late-Stage Diversification Method", 《J. ORG. CHEM.》 *
樊芳芳: "大麻酚类化合物的全合成", 《中国优秀硕士学位论文 工程科技I辑》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269717A (en) * 2019-05-23 2022-04-01 凯尔化学科技公司 Catalytic cannabinoid processes and precursors
EP3959193A4 (en) * 2019-05-23 2022-07-13 Kare Chemical Technologies Inc. Catalytic cannabinoid processes and precursors
CN113735709A (en) * 2021-09-17 2021-12-03 中国农业科学院农产品加工研究所 Cannabidiol-2-butyrate and application thereof
CN113735709B (en) * 2021-09-17 2022-03-18 中国农业科学院农产品加工研究所 Cannabidiol-2-butyrate and application thereof

Also Published As

Publication number Publication date
CN112062697B (en) 2023-09-01

Similar Documents

Publication Publication Date Title
Ohwada et al. Reaction of diphenylmethyl cations in a strong acid. Participation of carbodications with positive charge substantially delocalized over the aromatic rings
US11214581B2 (en) Method for preparing Crisaborole
CN111718228B (en) Method for synthesizing carboxylic acid for prolonging two carbon chains by one step from olefin
CN112062697A (en) M-benzene polyphenol derivative and preparation method thereof
EP2481742A1 (en) Preparation method of aromatic borate ester compound
Zhang et al. Photochemically catalyzed Diels–Alder reaction of arylimines with N-vinylpyrrolidinone and N-vinylcarbazole by 2, 4, 6-triphenylpyrylium salt: synthesis of 4-heterocycle-substituted tetrahydroquinoline derivatives
CN1995030B (en) Difluoro bezene derivative production method and produced intermediate
CN110437068B (en) Preparation method of aromatic methylation
CN112142694A (en) Polysubstituted tetrahydrofuran and tetrahydropyrane diene compound and preparation method thereof
CN113061077B (en) Alpha, alpha-dideuteroalcohol compounds, deuterated drugs and preparation method thereof
CN109575060B (en) Synthesis of spiro bisboron catalyst and application of spiro bisboron catalyst in hydrogenation reaction
CN110627772A (en) Pinene-fused chiral terpyridine bidentate compound and preparation method thereof
CN111747975B (en) Preparation method of bedaquiline racemate and intermediate thereof
Cheng et al. Difluorocarbene Chemistry: A Simple Transformation of 3, 3‐gem‐Difluorocyclopropenes to Cyclopropenones
CN111217847B (en) Thiosilane ligand, preparation method thereof and application thereof in aryl boronization catalytic reaction
CN111154498B (en) Preparation method of liquid crystal compound containing 1, 5-indan and difluoromethoxy bridge
CN113930246A (en) Liquid crystal compound and application thereof
CN113980686B (en) Preparation method of lateral o-difluorobenzene liquid crystal compound containing cyclohexyl
US3366688A (en) Process for the preparation of alpha, alpha-disubstituted-gema-hydroxyamines
EP2994472B1 (en) Process for the preparation of boronic acid intermediates
CN107759574B (en) 5-fluoro-1H-pyrazole-3-formate intermediate and synthesis method thereof
CN111689993A (en) Novel preparation method of chiral alpha-amino boric acid ester as key intermediate of boron-containing zomib drug
CN113121578B (en) Preparation method of benzoborazole compound
CN114907246B (en) Total synthesis method of vitamin A, derivative thereof and deuterated compound thereof
CN107857727A (en) It is a kind of（1R, 2S）With（1S, 2R）Shellfish reaches the preparation method of quinoline

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant